Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
86.9% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for Cartesian Therapeutics and Kymera Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Kymera Therapeutics | 1 | 2 | 23 | 1 | 2.89 |
Cartesian Therapeutics currently has a consensus price target of $32.60, suggesting a potential upside of 415.01%. Kymera Therapeutics has a consensus price target of $137.92, suggesting a potential upside of 8.08%. Given Cartesian Therapeutics’ higher possible upside, equities research analysts plainly believe Cartesian Therapeutics is more favorable than Kymera Therapeutics.
Earnings & Valuation
This table compares Cartesian Therapeutics and Kymera Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $1.48 million | 129.66 | -$130.30 million | ($5.94) | -1.07 |
| Kymera Therapeutics | $39.21 million | 277.84 | -$311.35 million | ($3.62) | -35.25 |
Cartesian Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cartesian Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Kymera Therapeutics | -285.33% | -22.39% | -20.48% |
Volatility and Risk
Cartesian Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
Summary
Kymera Therapeutics beats Cartesian Therapeutics on 9 of the 15 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
